KRAS-mutant CLL was sensitive to MEK inhibition, and showed increased viability with the BRAF inhibitor encorafenib, reflecting paradoxical BRAF activation (Supplemental Figure 17E). The gene discussed is KRAS; the disease is B-cell chronic lymphocytic leukemia.